-DOCSTART- -X- O
Abstract -X- _ B-Patient
Human -X- _ I-Patient
rhinovirus -X- _ I-Patient
lower -X- _ I-Patient
respiratory -X- _ I-Patient
tract -X- _ I-Patient
infection -X- _ I-Patient
( -X- _ I-Patient
LRTI -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
associated -X- _ O
with -X- _ O
mortality -X- _ O
after -X- _ O
hematopoietic -X- _ B-Patient
cell -X- _ I-Patient
transplantation -X- _ I-Patient
( -X- _ I-Patient
HCT -X- _ I-Patient
) -X- _ I-Patient
; -X- _ O
however -X- _ O
, -X- _ O
risk -X- _ O
factors -X- _ O
for -X- _ O
LRTI -X- _ O
are -X- _ O
not -X- _ O
well -X- _ O
characterized. -X- _ O
We -X- _ O
sought -X- _ O
to -X- _ O
develop -X- _ O
a -X- _ O
risk -X- _ O
score -X- _ O
for -X- _ O
progression -X- _ O
to -X- _ O
LRTI -X- _ O
from -X- _ O
upper -X- _ O
respiratory -X- _ O
tract -X- _ O
infection -X- _ O
( -X- _ O
URTI -X- _ O
) -X- _ O
in -X- _ O
HCT -X- _ O
recipients. -X- _ O
Risk -X- _ O
factors -X- _ O
for -X- _ O
LRTI -X- _ O
within -X- _ O
90 -X- _ O
days -X- _ O
were -X- _ O
analyzed -X- _ O
using -X- _ O
Cox -X- _ O
regression -X- _ O
among -X- _ O
HCT -X- _ B-Patient
recipients -X- _ I-Patient
with -X- _ I-Patient
rhinovirus -X- _ I-Patient
URTI -X- _ I-Patient
between -X- _ O
January -X- _ O
2009 -X- _ O
and -X- _ O
March -X- _ O
2016. -X- _ O
The -X- _ O
final -X- _ O
multivariable -X- _ O
model -X- _ O
included -X- _ O
factors -X- _ O
with -X- _ O
a -X- _ O
meaningful -X- _ O
effect -X- _ O
on -X- _ O
the -X- _ O
bootstrapped -X- _ O
optimism -X- _ O
corrected -X- _ O
concordance -X- _ O
statistic. -X- _ O
Weighted -X- _ O
score -X- _ O
contributions -X- _ O
based -X- _ O
on -X- _ O
hazard -X- _ O
ratios -X- _ O
were -X- _ O
determined. -X- _ O
Cumulative -X- _ O
incidence -X- _ O
curves -X- _ O
estimated -X- _ O
the -X- _ O
probability -X- _ O
of -X- _ O
LRTI -X- _ O
at -X- _ O
various -X- _ O
score -X- _ O
cut- -X- _ O
offs. -X- _ O
Of -X- _ B-Outcome
588 -X- _ I-Outcome
rhinovirus -X- _ I-Outcome
URTI -X- _ I-Outcome
events -X- _ I-Outcome
, -X- _ I-Outcome
100 -X- _ I-Outcome
( -X- _ I-Outcome
17 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
progressed -X- _ I-Outcome
to -X- _ I-Outcome
LRTI. -X- _ I-Outcome
In -X- _ I-Outcome
a -X- _ I-Outcome
final -X- _ I-Outcome
multivariable -X- _ I-Outcome
model -X- _ I-Outcome
allogeneic -X- _ I-Outcome
grafts -X- _ I-Outcome
, -X- _ I-Outcome
prior -X- _ I-Outcome
rhinovirus -X- _ I-Outcome
URTI -X- _ I-Outcome
, -X- _ I-Outcome
low -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
count -X- _ I-Outcome
, -X- _ I-Outcome
low -X- _ I-Outcome
albumin -X- _ I-Outcome
, -X- _ I-Outcome
positive -X- _ I-Outcome
cytomegalovirus -X- _ I-Outcome
serostatus -X- _ I-Outcome
, -X- _ I-Outcome
recipient -X- _ I-Outcome
statin -X- _ I-Outcome
use -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
steroid -X- _ I-Outcome
use -X- _ I-Outcome
â‰¥2 -X- _ I-Outcome
mg -X- _ I-Outcome
/ -X- _ I-Outcome
kg -X- _ I-Outcome
/ -X- _ I-Outcome
day -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
progression -X- _ I-Outcome
to -X- _ I-Outcome
LRTI. -X- _ I-Outcome
A -X- _ I-Outcome
weighted -X- _ I-Outcome
risk -X- _ I-Outcome
score -X- _ I-Outcome
cut-off -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
highest -X- _ I-Outcome
sensitivity -X- _ I-Outcome
and -X- _ I-Outcome
specificity -X- _ I-Outcome
was -X- _ I-Outcome
determined. -X- _ I-Outcome
Risk -X- _ I-Outcome
scores -X- _ I-Outcome
above -X- _ I-Outcome
this -X- _ I-Outcome
cut-off -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
progression -X- _ I-Outcome
to -X- _ I-Outcome
LRTI -X- _ I-Outcome
( -X- _ I-Outcome
cumulative -X- _ I-Outcome
incidence -X- _ I-Outcome
28 -X- _ I-Outcome
% -X- _ I-Outcome
versus -X- _ I-Outcome
11 -X- _ I-Outcome
% -X- _ I-Outcome
below -X- _ I-Outcome
cut-off -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.001 -X- _ I-Outcome
) -X- _ O
. -X- _ O
The -X- _ O
weighted -X- _ O
risk -X- _ O
score -X- _ O
for -X- _ O
progression -X- _ O
to -X- _ O
rhinovirus -X- _ O
LRTI -X- _ O
can -X- _ O
help -X- _ O
identify -X- _ O
and -X- _ O
stratify -X- _ O
patients -X- _ O
for -X- _ O
clinical -X- _ O
management -X- _ O
and -X- _ O
for -X- _ O
future -X- _ O
clinical -X- _ O
trials -X- _ O
of -X- _ O
therapeutics -X- _ O
in -X- _ O
HCT -X- _ O
recipients -X- _ O
. -X- _ O

